Your browser doesn't support javascript.
loading
Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Pinto, Filipe; Costa, Ângela M; Andrade, Raquel P; Reis, Rui Manuel.
Afiliación
  • Pinto F; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057, Braga, Portugal.
  • Costa ÂM; ICVS/3B's - PT Government Associate Laboratory, 4710-057, Braga, Portugal.
  • Andrade RP; I3S - Instituto de Investigação e Inovação em Saúde, University of Porto, 4200-135, Porto, Portugal.
  • Reis RM; Institute of Molecular Pathology and Immunology of the University of Porto - IPATIMUP, 4200-135, Porto, Portugal.
Neurotherapeutics ; 17(4): 2015-2027, 2020 10.
Article en En | MEDLINE | ID: mdl-32785847
Glioblastomas (GBMs) are the most aggressive tumor type of the central nervous system, mainly due to their high invasiveness and innate resistance to radiotherapy and chemotherapy, with temozolomide (TMZ) being the current standard therapy. Recently, brachyury was described as a novel tumor suppressor gene in gliomas, and its loss was associated with increased gliomagenesis. Here, we aimed to explore the role of brachyury as a suppressor of glioma invasion, stem cell features, and resistance to TMZ. Using gene-edited glioma cells to overexpress brachyury, we found that brachyury-positive cells exhibit reduced invasive and migratory capabilities and stem cell features. Importantly, these brachyury-expressing cells have increased expression of differentiation markers, which corroborates the results from human glioma samples and in vivo tumors. Glioma cells treated with retinoic acid increased the differentiation status with concomitant increased expression of brachyury. We then selected TMZ-resistant (SNB-19) and TMZ-responsive (A172 and U373) cell lines to evaluate the role of brachyury in the response to TMZ treatment. We observed that both exogenous and endogenous brachyury activation, through overexpression and retinoic acid treatment, are associated with TMZ sensitization in glioma-resistant cell lines. In this study, we demonstrate that brachyury expression can impair aggressive glioma features associated with treatment resistance. Finally, we provide the first evidence that brachyury can be a potential therapeutic target in GBM patients who do not respond to conventional chemotherapeutic drugs.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Diferenciación Celular / Antineoplásicos Alquilantes / Proteínas de Dominio T Box / Proteínas Fetales / Temozolomida / Glioma Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Neurotherapeutics Asunto de la revista: NEUROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Diferenciación Celular / Antineoplásicos Alquilantes / Proteínas de Dominio T Box / Proteínas Fetales / Temozolomida / Glioma Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Neurotherapeutics Asunto de la revista: NEUROLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Estados Unidos